TABLE 1.
Epidemiological, clinical, and immunological characteristics of the 31 HIV-2-infected patients
| Patient | Age (yr) | Gendera | Geographic origin (eventual epidemiological link with area of high endemicity) | Transmission group | Disease stage | Duration of follow-up (mos) | First CD4+ cell count available during follow- up (cells/mm3) | HIV-2 subtype (pol gene) | Antiretroviral therapy | PI (when administered) |
|---|---|---|---|---|---|---|---|---|---|---|
| MRT-1 | 38 | F | Algeria | Heterosexual | B | 71 | 210 | A | Yes | NFV |
| MRT-2 | 31 | M | Ivory Coast | Heterosexual | A | 9 | 37 | B | No | |
| MRT-3 | 46 | F | Guinea-Bissau | Heterosexual | A | 65 | 616 | NAc | No | |
| MRT-4 | 40 | F | France | Heterosexual | A | 34 | 445 | A | No | |
| MRT-5 | 35 | F | France (Congo) | Heterosexual | A | 22 | 676 | A | No | |
| MRT-6 | 35 | F | France (subsaharan Africa) | Heterosexual | A | 20 | 599 | NA | No | |
| MRT-7 | 47 | M | France (subsaharan Africa) | Heterosexual | A | 61 | 451 | A | Yes | RTV, NFV |
| MRT-8 | 52 | F | Ivory Coast | Transfusion | A | 119 | 308 | A | Yes | SQV, RTV, NFV, IDV |
| MRT-9 | 46 | F | Senegal | Heterosexual | A | 21 | 404 | A | No | |
| MRT-10 | 51 | M | Senegal | Heterosexual | A | 16 | 213 | NA | Yes | |
| MRT-11 | 40 | M | France | IVDUb, heterosexual | A | 54 | 1,883 | A | No | |
| MRT-12 | 38 | F | Burkina Faso | Heterosexual | A | 75 | 200 | A | ND | ND |
| MRT-13 | 27 | F | Senegal | Heterosexual | A | 9 | 580 | A | No | |
| MRT-14 | 41 | M | Guinea-Bissau | Unknown | A | 6 | 453 | A | No | |
| MRT-15 | 61 | F | No data | Heterosexual | A | 60 | 498 | A | No | |
| MRT-16 | 61 | M | Guinea-Bissau, Ivory Coast, Burkina Faso | Heterosexual | C | 12 | 62 | B | Yes | NFV |
| MRT-17 | 37 | M | Ivory Coast, Burkina Faso | Heterosexual | A | 133 | 464 | B | No | |
| MRT-18 | 50 | M | Central African Republic | Heterosexual | A | 11 | 1,019 | NA | No | |
| MRT-19 | 40 | M | Burkina Faso | Heterosexual | A | 8 | 578 | A | No | |
| MRT-20 | 47 | M | Guinea-Bissau | Heterosexual | C | 105 | 805 | A | Yes | IDV, NFV |
| MRT-21 | 40 | M | Senegal | Heterosexual | A | 57 | 1204 | A | No | |
| MRT-22 | 57 | M | Senegal | Heterosexual | A | 55 | 126 | A | Yes | NFV, LPV/r |
| MRT-23 | 47 | M | Guinea-Bissau | Heterosexual | C | 75 | 375 | A | ND | ND |
| MRT-24 | 41 | F | Guadeloupe | Heterosexual, transfusion | A | 38 | 156 | A | Yes | RTV, IDV, NFV |
| MRT-25 | 45 | F | France (Cape Verde islands) | Heterosexual | B | 52 | 69 | A | Yes | IDV, NFV, LPV/r, APV, RTV |
| MRT-26 | 56 | F | Guinea-Bissau | Heterosexual | A | 130 | 763 | A | No | |
| MRT-27 | 37 | F | Ghaana | Heterosexual | C | 20 | 136 | NA | Yes | IDV, LPV/r |
| MRT-28 | 72 | F | Senegal | Heterosexual | A | 21 | 507 | A | No | |
| MRT-29 | 45 | M | Senegal | Heterosexual | C | 12 | 10 | A | Yes | NFV |
| MRT-30 | 40 | F | Burkina Faso | Heterosexual | B | 139 | 600 | NA | Yes | |
| MRT-31 | 47 | M | Burkina Faso | Unknown | C (died) | 45 | NDd | B | Yes | NFV |
a
F, female; M, male.
b
IVDU, intravenous drug use.
c
NA, not available.
d
ND, no data.